Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
P 1 (3)

Trial Status

Unknown2
Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06874946Phase 1RecruitingPrimary

Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

NCT04679506UnknownPrimary

the Efficacy and Safety of CLAE in R/R T-ALL/LBL

NCT02742727Phase 1Unknown

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

NCT02337595Phase 1CompletedPrimary

Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation

Showing all 4 trials

Research Network

Activity Timeline